Illumina (NASDAQ:ILMN) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Other equities research analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Deutsche Bank set a $275.00 price target on shares of Illumina and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Piper Jaffray reiterated a “buy” rating and set a $269.00 price target on shares of Illumina in a research report on Tuesday, January 9th. Canaccord Genuity reiterated a “buy” rating and set a $265.00 price target (up previously from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. Finally, Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $260.00 to $275.00 in a research report on Monday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Illumina presently has an average rating of “Buy” and an average target price of $251.14.

Shares of NASDAQ:ILMN opened at $244.45 on Thursday. Illumina has a one year low of $167.98 and a one year high of $256.64. The company has a quick ratio of 3.55, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. The company has a market cap of $35,666.61, a PE ratio of 61.11, a price-to-earnings-growth ratio of 2.82 and a beta of 0.89.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The company had revenue of $782.00 million during the quarter, compared to analysts’ expectations of $744.30 million. During the same quarter in the previous year, the company earned $0.64 EPS. Illumina’s revenue was up 30.8% on a year-over-year basis. equities research analysts forecast that Illumina will post 4.87 earnings per share for the current fiscal year.

In other Illumina news, Director A Blaine Bowman sold 3,000 shares of Illumina stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $230.82, for a total value of $692,460.00. Following the transaction, the director now owns 19,868 shares of the company’s stock, valued at $4,585,931.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Oene Mark Van sold 1,400 shares of Illumina stock in a transaction that occurred on Thursday, April 12th. The shares were sold at an average price of $238.48, for a total transaction of $333,872.00. Following the completion of the transaction, the senior vice president now directly owns 12,217 shares in the company, valued at approximately $2,913,510.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,008 shares of company stock valued at $4,130,075. Corporate insiders own 0.54% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Fairfield Bush & CO. lifted its stake in Illumina by 1.4% in the fourth quarter. Fairfield Bush & CO. now owns 18,985 shares of the life sciences company’s stock valued at $4,148,000 after buying an additional 255 shares in the last quarter. Xact Kapitalforvaltning AB lifted its stake in Illumina by 10.4% in the fourth quarter. Xact Kapitalforvaltning AB now owns 25,667 shares of the life sciences company’s stock valued at $5,608,000 after buying an additional 2,425 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Illumina by 634.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 14,527 shares of the life sciences company’s stock valued at $3,174,000 after buying an additional 12,549 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Illumina by 14.2% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 58,048 shares of the life sciences company’s stock valued at $12,683,000 after buying an additional 7,202 shares in the last quarter. Finally, Slow Capital Inc. bought a new position in Illumina in the fourth quarter valued at approximately $1,931,000. 91.70% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.